- Home
- MCRB vs STRW Comparison
MCRB vs STRW Comparison
Compare MCRB & STRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- STRW
- Stock Information
- Founded
- MCRB 2010
- STRW 2015
- Country
- MCRB United States
- STRW United States
- Employees
- MCRB N/A
- STRW N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- STRW Real Estate Investment Trusts
- Sector
- MCRB Health Care
- STRW Real Estate
- Exchange
- MCRB Nasdaq
- STRW Nasdaq
- Market Cap
- MCRB 165.3M
- STRW 154.1M
- IPO Year
- MCRB 2015
- STRW N/A
- Fundamental
- Price
- MCRB $17.23
- STRW $12.51
- Analyst Decision
- MCRB Hold
- STRW Strong Buy
- Analyst Count
- MCRB 4
- STRW 4
- Target Price
- MCRB $73.67
- STRW $12.72
- AVG Volume (30 Days)
- MCRB 245.5K
- STRW 25.5K
- Earning Date
- MCRB 11-12-2025
- STRW 11-10-2025
- Dividend Yield
- MCRB N/A
- STRW 4.55%
- EPS Growth
- MCRB N/A
- STRW 27.31
- EPS
- MCRB 10.22
- STRW 0.59
- Revenue
- MCRB N/A
- STRW $135,145,000.00
- Revenue This Year
- MCRB N/A
- STRW $33.39
- Revenue Next Year
- MCRB N/A
- STRW $5.21
- P/E Ratio
- MCRB $1.68
- STRW $20.78
- Revenue Growth
- MCRB N/A
- STRW 24.72
- 52 Week Low
- MCRB $6.53
- STRW $8.70
- 52 Week High
- MCRB $24.67
- STRW $12.90
- Technical
- Relative Strength Index (RSI)
- MCRB 52.55
- STRW 61.03
- Support Level
- MCRB $17.00
- STRW $11.40
- Resistance Level
- MCRB $24.67
- STRW $12.81
- Average True Range (ATR)
- MCRB 1.79
- STRW 0.45
- MACD
- MCRB -1.40
- STRW 0.03
- Stochastic Oscillator
- MCRB 69.86
- STRW 79.80
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.